HIV Vaccine Awareness Day Recognizes Global Efforts
May 21, 2015 11:31 ET
|
International Centre for Infectious Disease
WINNIPEG, May 21, 2015 (GLOBE NEWSWIRE) -- Recent scientific discoveries in HIV illustrate the need for partnerships and collaboration in the effort to develop a safe and effective HIV vaccine. But...
VaxInnate Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets
May 13, 2015 08:00 ET
|
Scienta Communications
Cranbury, NJ, May 13, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced two strategic
promotions and two additions to...
Get Added Protection Against H3N2 with A.Vogel's Clinically Proven Echinaforce(R)
February 03, 2015 10:01 ET
|
Bioforce Canada
MONTREAL, Feb. 3, 2015 (GLOBE NEWSWIRE) -- A recent study confirms that the 2014-2015 flu vaccine offers little or no protection from this year's predominant influenza strain H3N2.
The research,...
Studies Show that Vaccinated Individuals Spread Disease
February 02, 2015 14:34 ET
|
Weston A. Price Foundation
Washington, D.C., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Health officials are blaming unvaccinated children for the
recent measles outbreak that started at Disneyland. However, with
no blood tests proving...
Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study
February 02, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the results of a new efficacy study of Ampligen® in a...
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
November 18, 2014 05:44 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 18, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was well tolerated
...
Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which is Linked to High Mortality in Man
November 17, 2014 09:08 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it had received a new research report from Professor...
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
November 17, 2014 08:01 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Nov 17, 2014) - Bionor Pharma ASA (OSLO: BIONOR)
Treatment with Vacc-4x + Revlimid (lenalidomide) was safe and well tolerated
...
Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)
October 30, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today a new peer reviewed publication entitled, "The Quest for...
Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
October 20, 2014 12:00 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...